NCT03276273 Bispectral-Electroencephalography (EEG) in First Time Hemodialysis
| NCT ID | NCT03276273 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Suez Canal University |
| Condition | Renal Failure Acute Chronic |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2017-05-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2017-05-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The severity of minimal dialysis disequilibrium syndrome (DDS) is currently detected and graded clinically using clinical criteria. Bispectral Index (BIS), an electroencephalographic (EEG) derived parameter is widely used in anesthesia and Critical Care setting to detect effects of anesthetic/hypnotic drugs. The aim of our study was to assess the discriminative power of BIS monitoring to accurately detect DDS.
Eligibility Criteria
Inclusion Criteria: * First Time renal Dialysis Exclusion Criteria: * subjects' consumption of sedatives/hypnotics psychotropic drugs, or concomitant neurological disorders affecting mental state such as hepatic encephalopathy, stroke, stupor or dementia and renal transplant patients.
Contact & Investigator
Ashraf Dahaba, MD
PRINCIPAL INVESTIGATOR
Guest Professor
Frequently Asked Questions
Who can join the NCT03276273 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Renal Failure Acute Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03276273 currently recruiting?
Yes, NCT03276273 is actively recruiting participants. Contact the research team at ashraf.dahaba@medunigraz.at for enrollment information.
Where is the NCT03276273 trial being conducted?
This trial is being conducted at Dalian, China, Cairo, Egypt.
Who is sponsoring the NCT03276273 clinical trial?
NCT03276273 is sponsored by Suez Canal University. The principal investigator is Ashraf Dahaba, MD at Guest Professor. The trial plans to enroll 20 participants.